/>

Post a Comment Print Share on Facebook
Featured Top News Hot News Online Casinos Corona

reads.

Age-related macular degeneration, the Europe approves therapy with fewer injections
CASES of blindness due to age-related macular degeneration will grow from 40 million to 120 with enormous implications on the quality of life of people, though living longer, are not able to be fully autonomous. With the aim of increasing the awareness of older people about this disease, the Centro Ambrosiano Oftalmico (Camo) has undertaken for the third year in a screening campaign in the whole country about this disease in Italy, affecting more than a million people every year and it is manifested with 80 thousand new cases. Even if there is not yet a cure for macular degeneration, in these days came the good news: the european Commission has approved brolucizumab, solution for injection for the treatment of age-related macular degeneration exudative. The two forms of age-related macular degeneration The age-related macular degeneration can be of two types: the form of 'dry' (atrophic) is the most common (85%) and is the slowest to give a drop of the view; and the form of 'wet' (neovascular), which affects 10-15% of patients but is responsible for 90% of all cases of severe visual reduction. The facts, this form is one of the leading causes of severe vision loss and blindness in people over the age of 65 years. The first symptoms include blurred vision or wavy, with the progression of the disease, patients lose central vision and cannot, therefore, see objects located directly in front of them.
The new medication Currently in patients with age-related macular degeneration exudative, which are for the most part older people, often encounter significant difficulties in the management of the disease. Brolucizumab is the first anti-VEGF drug approved by the European Union to demonstrate superiority with respect to aflibercept in the resolution of the fluid, retinal, a key indicator of disease activity. This drug also offers the possibility to start therapy with a dosing interval of three months immediately after the loading phase. This has the advantage, compared to other medications, be a small molecule that penetrates very well inside of the retina. Promptly disappears from the bloodstream, thus reducing the risk of systemic side effects.
How does age-related macular degeneration exudative is a degenerative disease chronic of the view, caused by VEGF, a protein that is, the excess of which promotes the growth of abnormal blood vessels under the macula (the area of the retina responsible for sharp central vision). Fluid leaking from these neovasi alters the normal retinal structure and compromising the vision. By inhibiting VEGF, brolucizumab is designed to suppress the growth of abnormal blood vessels, and the potential for leakage of fluid in the retina. Clinical studies The approval for brolucizumab it is based on the results of clinical studies of phase III Hawk, and Harrier in the course of which brolucizumab has demonstrated non-inferiority compared to aflibercept in the change in median best visual acuity corrected to a year. In both clinical studies, about 30% of patients gained at least 15 letters in a year. “This approval represents a step forward for patients in Europe who are in search of a new therapeutic option to help them to keep the view – and thus the autonomy – longer,” said Christina Fasser, president of Retina International. “This could really help to simplify the life of not only patients, but also of those who care”.
prevention month, The month of prevention for age-related macular degeneration has been called by the Camo together with the San Raffaele Hospital, and Ospedale Fatebenefratelli-Lot of Milan, with the patronage of the Ministry of Health and the Society of Ophthalmology (Soi) and the international Agency for the prevention of blindness (Iapb). You are made available the ophthalmologists of 26 eye care centers of 13 Italian regions. The campaign takes place until February 28. In this month all the people over 60 years of age can book a free visit at one of the 26 centers by consulting the website www.curagliocchi.it .

"The Republic will fight always in defense of the freedom of information, to its readers and to all those who have at heart the principles of democracy and civil coexistence"

Carlo Verdelli SUBSCRIBERS TO REPUBLIC © Reproduction reserved Today on “Aliens exterminated”. Massacre shakes Germany The bomber: “The secret service I spy”. The delirium of the bank that he wanted to wake up the whites That black monster that scares the Germany and Italy Instead of the one that sees Liliana Segre reason, the culture there aid
the Republic
Avatar
Your Name
Post a Comment
Characters Left:
Your comment has been forwarded to the administrator for approval.×
Warning! Will constitute a criminal offense, illegal, threatening, offensive, insulting and swearing, derogatory, defamatory, vulgar, pornographic, indecent, personality rights, damaging or similar nature in the nature of all kinds of financial content, legal, criminal and administrative responsibility for the content of the sender member / members are belong.